Teaming Up for Better Outcomes
Our experience with partnerships has taught us that bringing together the right people through a transparent process is critical to successful collaboration. Our teams in Global External Research and Development, Corporate Business Development, Corporate Finance Investment Banking, and the Office of Alliance Management are focused on identifying, developing, and commercializing the products and technologies that will yield improved outcomes as well as greater value for patients and partners alike.
Efficient Process, Flexible Deals
Our approach includes three straightforward steps:
Identify opportunity
We seek out new opportunities in all parts of the world, across a diverse set of therapeutic platforms and technologies.
Negotiate agreement
Our goal is to reach a mutually beneficial deal structure that everyone is comfortable with.
Implement and manage
Setting goals and encouraging open communication keeps everyone aligned and moving toward success.
At each stage, you'll work closely with individuals who have deep experience in the relevant scientific and commercial possibilities for your innovative product or technology. And while our process is well-established, we also offer great flexibility when it comes to negotiation, deal structure, and ongoing alliance management.
Global External Research and Development (GER&D)
GER&D is responsible for the identification, coordination, and scientific evaluation of new opportunities. The group comprises experienced scientists who review potential collaborations to evaluate mutual fit. GER&D also can call on the extensive expertise of Lilly Research Laboratories to provide further analysis and guidance.
Corporate Business Development (CBD)
CBD is responsible for forming the alliances that further innovation. Group members have the abilities and resources necessary to secure licensing, alliance, and acquisition opportunities.
To do all this successfully, CBD professionals join in the earliest stages of a potential partnership, working closely to come to agreement by:
- Building a shared perspective of alliance expectations and goals
- Communicating regularly to make sure everything is on track
- Ensuring timely scientific, legal, and alliance management involvement
- Offering flexibility and creativity in risk and reward sharing
Examples of partnering models include:
- Co-development
- In-licensing
- Product acquisition
- Co-promotion/co-marketing
- Research and/or novel discovery collaborations
- Out-licensing/partnering
- Academic collaborations
Corporate Finance—Investment Banking (CFIB)
CFIB supports Corporate Business Development in-licensing and corporate projects through economic and financial-implication analytical work. CFIB is responsible for leading the company's merger and acquisition projects as a close partner with Corporate Business Development and Global External Research and Development. With an emphasis on investment bank relationship management, valuation, financial analysis, merger and acquisition negotiation, acquisition-transaction due diligence, integration planning and execution, and other transaction-related disciplines, our CFIB professionals have a proven track record and the experience required to address the complete range of deal and structuring options.
Office of Alliance Management (OAM)
OAM is responsible for implementing and bringing benefit to each alliance partner after an agreement is signed. As valuable navigation experts, OAM representatives effectively guide and help partnerships grow into lasting business relationships, including the many productive alliances active today. Our experienced alliance managers support the partners' strategic, operational, and cultural alignment to optimize resources and meet alliance goals.
As founding members of the Association of Strategic Alliance Professionals (ASAP), OAM team leaders pledge to:
- Serve as an advocate within Lilly for the alliance partner
- Develop and use best partnering practices
- Ask for and incorporate feedback regarding ongoing operations
- Train and support Lilly staff to fully enable cross-cultural collaboration
